Asset Details
Do you wish to reserve the book?
Plasma GFAP in Parkinson’s disease with cognitive impairment and its potential to predict conversion to dementia
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Plasma GFAP in Parkinson’s disease with cognitive impairment and its potential to predict conversion to dementia
Do you wish to request the book?
Plasma GFAP in Parkinson’s disease with cognitive impairment and its potential to predict conversion to dementia
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Plasma GFAP in Parkinson’s disease with cognitive impairment and its potential to predict conversion to dementia
2023
Overview
Glial fibrillary acidic protein (GFAP) has been suggested as a biomarker for reactive astrogliosis. We measured the levels of plasma GFAP by Simoa in 60 patients with PD with normal cognition, 63 with mild cognitive impairment (PD-MCI), 24 with dementia (PDD) and 15 healthy controls. A subgroup of patients with PD-MCI (
n
= 31) was followed up for 4.1 ± 2.3 years. Compared with healthy controls, plasma GFAP levels were elevated in patients with PDD (adjusted
P
< 0.001) and PD-MCI (adjusted
P
= 0.013) and were negatively correlated with the Mini Mental State Examination (MMSE) score in PD participants. Plasma GFAP predicted MCI-to-dementia conversion with an AUC of 0.90, higher than NfL, Tau and pTau181. Our results support that plasma GFAP has potential value for distinguishing patients with PDD, and predicting MCI-to-dementia conversion in PD.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
Subject
